Cargando…

Prospective longitudinal study on fear of cancer recurrence in patients newly diagnosed with head and neck cancer: Course, trajectories, and associated factors

BACKGROUND: This study assessed the course of fear of cancer recurrence (FCR) in patients newly diagnosed with head and neck cancer (HNC), identified FCR trajectories and factors associated with FCR trajectories. METHODS: Six hundred and seventeen HNC patients from the NET‐QUBIC cohort study complet...

Descripción completa

Detalles Bibliográficos
Autores principales: Deuning‐Smit, Esther, Custers, José A. E., Miroševič, Špela, Takes, Robert P., Jansen, Femke, Langendijk, Johannes A., Terhaard, Chris H. J., Baatenburg de Jong, Robert J., Leemans, C. René, Smit, Johannes H., Kwakkenbos, Linda, Verdonck‐de Leeuw, Irma M., Prins, Judith B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305148/
https://www.ncbi.nlm.nih.gov/pubmed/35084079
http://dx.doi.org/10.1002/hed.26985
Descripción
Sumario:BACKGROUND: This study assessed the course of fear of cancer recurrence (FCR) in patients newly diagnosed with head and neck cancer (HNC), identified FCR trajectories and factors associated with FCR trajectories. METHODS: Six hundred and seventeen HNC patients from the NET‐QUBIC cohort study completed the Cancer Worry Scale‐6 at diagnosis, 3 and 6 months post‐treatment. FCR trajectories were identified using Latent Class Growth Analysis. Associations were explored between FCR trajectories and baseline demographic and medical variables, coping and self‐efficacy. RESULTS: Overall, FCR decreased slightly between baseline and 3 months post‐treatment and remained stable up to 6 months. Two FCR trajectories were identified: “high stable” (n = 125) and “low declining” (n = 492). Patients with high stable FCR were younger, reported more negative adjustment, passive coping, and reassuring thoughts, and less avoidance. CONCLUSIONS: The majority of HNC patients have low declining FCR after diagnosis, but one in five patients experience persistent high FCR up to 6 months post‐treatment.